

SGNLVA-001: A PHASE 1 OPEN-LABEL DOSE ESCALATION AND EXPANSION STUDY OF SGN-LIV1A ADMINISTERED WEEKLY IN BREAST CANCER (TRIAL IN PROGRESS)

Heather Beckwith¹, Diana Medgyesy², Jame Abraham³, Rita Nanda⁴, Katherine H. R. Tkaczuk⁵, Ian Krop⁶, Lajos Pusztai⁷, Shanu Modi⁸, Monica Mita⁹, Jennifer Specht¹⁰, Sara Hurvitz¹¹, Hyo Han¹², Kevin Kalinsky¹³, Sharon Wilks¹⁴, Joyce O'Shaughnessy¹⁵, Lowell Hart¹⁶, Hope Rugo¹⁷, Zahi Mitri¹⁸, Phillip M. Garfin¹⁹, Howard Burris²⁰

¹University of Minnesota, Minneapolis, MN; ²Front Range Cancer Specialists, Fort Collins, CO; ³National Surgical Adjuvant Breast and Bowel Project Foundation and Cleveland Clinic, Cleveland, OH; ⁴The University of Chicago, Chicago, IL; ⁵University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD; ⁶Dana-Farber Cancer Institute, Boston, MA; ⁷Yale University Cancer Center, New Haven, CT; ⁸Memorial Sloan Kettering Cancer Center, New York, NY; ⁹Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; ¹⁰University of Washington, Seattle, WA; ¹¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ¹²Moffitt Cancer Center, Tampa, FL; ¹³Herbert Irving Comprehensive Cancer Center, New York, NY; ¹⁴Texas Oncology, San Antonio, TX; ¹⁵Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; ¹⁶Florida Cancer Specialists and Research Institute, Fort Myers, FL; ¹⁷University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; ¹⁸Oregon Health and Science University, Portland, OR; ¹⁹Seattle Genetics, Bothell, WA; ²⁰Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

Breast Cancer Background


- Breast cancer is the most common malignancy in women in the US.
- Approximately one-third of these patients will eventually develop recurrent or metastatic disease.⁴
- The prognosis is poor in those with metastatic breast cancer (mBC), with a 5-year relative survival of less than 24%.¹
- The current therapies for metastatic disease delay disease progression, but are not curative.
- This is a phase 1 dose-escalation and dose-expansion study to define the safety and tolerability and establish a maximum tolerated dose (MTD) of once weekly (q1wk) ladiratuzumab vedotin (LV) in patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2 (HER2) negative mBC and metastatic triple negative breast cancer (mTNBC).
- LV is an investigational antibody-drug conjugate (ADC) that has been shown to be active and tolerable in mBC at a recommended dose of 2.5 mg/kg every 21 days.³
- More frequent, fractionated dosing has improved the activity and/or safety of other ADCs.³
- More than 200 patients in Parts A–D of this trial have received LV administered q3wk, allowing for accurate pharmacokinetic modeling.
- Data demonstrates fractionated dosing has led to improved safety, efficacy, or both safety and efficacy for other ADCs.

LIV-1

- LIV-1
 - Transmembrane protein that has been found in breast cancer.⁶
 - Expression has been linked with malignant progression to metastasis and is associated with lymph node involvement in breast cancer.²

Ladiratuzumab Vedotin (LV) Proposed Mechanism of Action

- After binding LIV-1, LV is internalized and trafficked through the endocytic pathway to reach the lysosomes.
- Degradation of the drug linker in lysosomes releases monomethyl auristatin E (MMAE).
- LV-mediated delivery of MMAE drives antitumor activity through:
 - Microtubule disruption, cell cycle arrest, and apoptosis.
 - Inducing ICD.⁵




New dose escalation and dose expansion cohorts have opened in Study SGNLVA-001. Patients with endocrine-resistant HR-positive/HER2-negative metastatic breast cancer and metastatic triple-negative breast cancer will receive weekly dosing of LV.

Study Design

- This on-going, phase 1, dose-escalation study is enrolling patients with HR+/HER2-negative and mTNBC irrespective of LIV-1-expressing to define the safety and tolerability and establish a MTD of weekly LV dosing as monotherapy.
- Part E of this study consists of two parts: Dose Escalation and Dose Expansion.

Dose Escalation | HR+/HER2-negative



Dose Expansion | HR+/HER2-negative and mTNBC

- Sample size: up to 82 patients (42 HR+/HER2-negative and 40 mTNBC) into dose escalation and dose expansion cohorts.
- Dosing schedule: q1wk dosing of LV administered on Day 1, Day 8, and Day 15 in every 3-week cycle.

Objectives

Primary Objective

- To evaluate the safety and tolerability of q1wk dosing of LV in patients with mTNBC and endocrine-resistant ER+ or PR+ (HR+)/HER2-negative mBC.
- To identify the MTD of LV.

Secondary Objectives

- To assess the antitumor activity of LV.
- To assess the pharmacokinetics of LV.
- To assess the immunogenicity of LV.

Endpoints

Safety Endpoints

- Type, incidence, severity, seriousness, and relatedness of adverse events (AEs).
- Type, incidence, and severity of laboratory abnormalities.
- Incidence of dose-limiting toxicity.

Efficacy Endpoints

- ORR, confirmed and unconfirmed.
- Duration of response (DOR).
- Progression-free survival (PFS) and PFS ratio relative to prior therapy.
- Overall Survival (OS)

Pharmacokinetics and Pharmacodynamics

- Markers of pharmacokinetics and pharmacodynamics will be assessed.

Eligibility

Key Inclusion Criteria

- Females ≥18 years of age.
- Pathologically and radiologically-confirmed HR+/HER2-negative mBC or mTNBC.
- At least 1 measurable lesion per Response Evaluation Criteria for Solid Tumors (RECIST) v1.1.
- Patients with HR+/HER2-negative disease must have received no more than 1 prior line of cytotoxic chemotherapy in the locally advanced (LA)/mBC setting, either as single agent or combination therapy, and must be refractory to hormone therapy.
- Patients with mTNBC must have received 1 prior line of cytotoxic chemotherapy in the LA/mBC setting.
- Adequate organ function.
- Eastern Cooperative Oncology Group (ECOG) status of ≤1.
- Patients with brain lesions must have received definitive treatment of the lesions.

Key Exclusion Criteria

- Pre-existing neuropathy of ≥ Grade 2.
- History of another primary invasive malignancy that has not been in remission for at least 3 years.
- Any active Grade 3 or higher (per the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 [NCI CTCAE v4.03]) viral, bacterial, or fungal infection within 2 weeks prior to the first dose of LV.
- Positive for hepatitis B by surface antigen expression, active hepatitis C infection or a known history of being seropositive for HIV.
- Documented history of a cerebral vascular event.
- Prior treatment with LV or prior treatment with an MMAE-containing therapy.

Assessments

Safety Assessments

- All patients will be followed for safety .
- Safety will be monitored by the safety monitoring committee during dose escalation and will include:
 - Surveillance and recording of AEs including serious adverse events.
 - Recording of concomitant medication and measurements of protocol-specified physical examination findings and laboratory tests.

Response Assessments

- Response assessed every 2 cycles of treatment in the first ten cycles and every fourth cycle thereafter. Clinical response determined by the investigator at each assessment according to RECIST v1.1. (Clinical response may also be assessed by BICR according to RECIST v1.1.)
- For patients who discontinue treatment prior to disease progression, assessments will be conducted every 6 weeks (±1 week) starting from the most recent tumor assessment until progression or the initiation of a new anticancer treatment.
- All patients will be followed for survival until death or study closure, whichever occurs first. Patients will be followed every 12 weeks (±1 week) for the first year, and then every 24 weeks (±1 week) thereafter.

Study Sites and Completion Dates

- 34 sites across United States.
- Study start: October 22, 2013.
- Estimated study completion: March 31, 2022.

Acknowledgements

- Thank you to our patients and their families for their participation in the study, and to all research personnel for their support of this important trial.
- This study is funded by Seattle Genetics, Inc.

References

- Howlader N, et al. SEER Cancer Statistics Review, 1975-2010. National Cancer Institute. Bethesda, MD based on November 2012 SEER data submission, posted to the SEER web site, 2013.
- Manning DL, et al. Eur J Cancer 1994; 30A(5): 675–8.
- Modi S, et al. Proceedings of the 2017 San Antonio Breast Cancer Symposium: Abstract PD3-14. 2017.
- O'Shaughnessy J. Oncologist 2005; 10(Suppl 3): 20-9.
- Specht J, et al. Ann Oncol 2018; 29(Suppl 8): viii92.
- Taylor KM, et al. Biochem J 2003; 375(Pt 1): 51-9.

Copies of this poster obtained through Quick Response (QR) code are for personal use only and may not be reproduced without permission from the author of this poster, **Heather Beckwith, einho003@umn.edu**.



Abstract No. TSP1104

American Society of Clinical Oncology
May 29-31, 2020

Disclosures: Beckwith: Boehringer Ingelheim and Seattle Genetics. Medgyesy: Seattle Genetics. Abraham: Pfizer and Seattle Genetics. Nanda: Abbvie, Adaro Biotech, AstraZeneca, Athenex, Celgene, Corcept Therapeutics, Daiichi Sankyo, G1 Therapeutics, Genentech/Roche, Immunomedics, Ionis Pharmaceuticals, MacroGenics, Merck, Odonate Therapeutics, Pfizer, and Seattle Genetics. Tkaczuk: Abbott/AbbVie, Amgen, Angiochem, Biocrypt, Biomarin, Cascadian Therapeutics, Daiichi Sankyo, Eisai, Genentech/Roche, Nektar, Novartis, Odonate Therapeutics, Puma Biotechnology, Seattle Genetics, and Tapimmune Inc. Krop: AMAG Pharmaceuticals, AstraZeneca, Celtrion, Context Therapeutics, Daiichi Sankyo, Genentech, Genentech/Roche, Ionis Pharmaceuticals, MacroGenics, Merck, Novartis, Pfizer, Seattle Genetics, and Takeda Pharmaceuticals. Pusztai: Amgen, AstraZeneca, Athenex, Bristol-Myers Squibb, Clovis Oncology, Eisai, Genentech, H3 Biomedicine, Immunomedics, Merck, NanoString Technologies, Novartis, Roche/Genentech, Seattle Genetics, and Syndax. Modi: Daiichi, Daiichi Sankyo, Genentech, Novartis, Roche/Genentech, Seattle Genetics, and Synta Pharmaceuticals. Mita: Seattle Genetics. Specht: Cascadian Therapeutics, Daiichi Sankyo, Digipharma, Genentech/Roche, GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Merck, Novartis, OBI Pharma, Pfizer, Piner Pharmaceuticals, Puma Biotechnology, Radius Health, Roche, Sanofi, and Seattle Genetics. Han: Abbvie, Bristol-Myers Squibb, G1 Therapeutics, Horizon Oncology Research, Lilly, Novartis, Pfizer, President Therapeutics, Seattle Genetics, Tapimmune Inc., and Tesaro. Kalinsky: Acetylon Pharmaceuticals, Amgen, Array BioPharma, AstraZeneca, BioTherapeutics, Calithera Biosciences, CytoX Therapeutics, Eisai, Genentech, Genentech/Roche, Immunomedics, Incyte, Ipsen, Lilly, Novartis, Odonate Therapeutics, Pfizer, Seattle Genetics, and Zeno Pharmaceuticals. Wilks: Seattle Genetics. O'Shaughnessy: Abbvie, Agendia, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Eisai, Genentech, Genomic Health, GRAIL, HERON, Immunomedics, Ipsen, Jounce Therapeutics, Lilly, Merck, Myriad Pharmaceuticals, Novartis, Odonate Therapeutics, Pfizer, Puma Biotechnology, Roche, Samsung, Sanofi, Seattle Genetics, and Syndax. Hart: Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, G1 Therapeutics, Genentech, Genentech/Roche, Lilly, Merck, NanoString Technologies, Novartis, Pfizer, and Seattle Genetics. Rugo: Amgen, AstraZeneca, Daiichi Sankyo, Eisai, Genentech, Immunomedics, Lilly, MacroGenics, Merck, Mylan, Novartis, OBI Pharma, Odonate Therapeutics, Pfizer, Puma, Biotechnology, and Seattle Genetics. Mitri: AstraZeneca, Daiichi Sankyo, Lilly, Novartis, Pfizer/EMD Serono, Puma Biotechnology, Radius Health, Samsung Biopharm, and Seattle Genetics. Garfin: Employee and equity ownership in Seattle Genetics, Inc., Immunomedics Burris: Agios, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, CytoX Therapeutics, FORMA Therapeutics, HCA Healthcare, Incyte, Jounce Therapeutics, Lilly, MacroGenics, MedImmune, Merck, Moderna Therapeutics, Novartis, Roche/Genentech, and Seattle Genetics.